<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38413280</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>19</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.</ArticleTitle><Pagination><StartPage>2065</StartPage><EndPage>2071</EndPage><MedlinePgn>2065-2071</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.02.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)00219-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Assess the level of measles vaccine-induced neutralizing antibodies against the D8 genotype and the persistence of humoral and cell-mediated immunity in children who received their first dose of the measles, mumps, and rubella vaccine eight years previously.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Measles-specific IgG and neutralizing antibodies were determined in serum using ELISA and plaque reduction neutralization test, respectively. Cellular response was evaluated from peripheral blood mononuclear cells (PBMC). IFN-γ-secreting cells, memory B and T cells, and immunological mediators were assayed by ELISpot, flow cytometry, and multiplex liquid microarray assay, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Antibody concentrations declined over time; however, the vaccine-induced neutralizing antibodies' effect against D8 and vaccinal genotypes persisted. PBMC stimulated with the vaccine virus exhibited specific IFN- γ-measles-secreting responses in most participants. Participants with high levels of neutralizing antibodies showed a higher proportion of activated B cells compared to participants with low levels of neutralizing antibodies, while proportions of memory CD4+ and CD8+ T cells were similar between these groups. PBMC supernatant cytokine levels showed a significant difference between stimulated and non-stimulated conditions for IL-2, TNF-α, IL-10, and CXCL10.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite the decline in antibody concentrations over time, the participants still demonstrated neutralizing capacity against the measles D8 genotype five to eight years after the second dose of the measles, mumps, and rubella vaccine. Additionally, most of the enrolled children exhibited cell-mediated immunity responses to measles virus stimulation.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kegele Lignani</LastName><ForeName>Letícia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil. Electronic address: leticia.lignani@bio.fiocruz.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vasconcellos Carvalhaes de Oliveira</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matos Dos Santos</LastName><ForeName>Eliane</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonio Bastos Camacho</LastName><ForeName>Luiz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública Sérgio Arouca, Rua Leopoldo Bulhões, 1480, Manguinhos, CEP 21040-360 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis Xavier</LastName><ForeName>Janaína</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regina da Silva E Sá</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universidade Federal do Estado do Rio de Janeiro, Instituto de Saúde Coletiva, Rua Professor Gabizo, 264, 3° andar, Tijuca, CEP 20271-062 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendonça Siqueira</LastName><ForeName>Marilda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques Vieira da Silva</LastName><ForeName>Andréa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil Melgaço</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos Alves</LastName><ForeName>Nathalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lourdes de Sousa Maia</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil, 4365, Manguinhos, CEP 21041-250 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caetano Prates Melo</LastName><ForeName>Enirtes</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública Sérgio Arouca, Rua Leopoldo Bulhões, 1480, Manguinhos, CEP 21040-360 Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022542">Measles-Mumps-Rubella Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008458">Measles Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009107" MajorTopicYN="Y">Mumps</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022542" MajorTopicYN="N">Measles-Mumps-Rubella Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008457" MajorTopicYN="Y">Measles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008458" MajorTopicYN="N">Measles Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012409" MajorTopicYN="Y">Rubella</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cell-mediated immunity</Keyword><Keyword MajorTopicYN="N">Measles vaccine</Keyword><Keyword MajorTopicYN="N">Neutralizing antibodies</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: LKL, EMS, MLSM, JRX, AMVS, JGM, and NSA are employees of the Immunobiological Technology Institute/Oswaldo CruzFoundation (Bio-Manguinhos/Fiocruz), Marketing Authorization Holder of themeasles, mumps, and rubella vaccine used inthe Brazilian healthcare system.The other authors declare that they have no known competing financial interests or personal relationships that might have influenced the work reported in this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>28</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>21</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38413280</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.02.060</ArticleId><ArticleId IdType="pii">S0264-410X(24)00219-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle>